HAND-FOOT SKIN REACTION INCREASES WITH CUMULATIVE SORAFENIB DOSE AND WITH COMBINATION ANTI-VEGF THERAPY

PURPOSE: Sorafenib, a vascular endothelial growth factor receptor (VEGFR)-2 and RAF-kinase inhibitor, commonly causes skin toxicity. We retrospectively analyzed dermatologic toxicity in patients receiving combined anti-angiogenic therapy sorafenib and bevacizumab. EXPERIMENTAL DESIGN: Castration-res...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Azad, Nilofer S., Aragon-Ching, Jeanny B., Dahut, William L., Gutierrez, Martin, Figg, William D., Jain, Lokesh, Steinberg, Seth M., Turner, Maria L., Kohn, Elise C., Kong, Heidi H.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2009
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2718558/
https://ncbi.nlm.nih.gov/pubmed/19228742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-1141
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia